Linezolida Aurobindo

Linezolid, the active ingredient in Linezolida Aurobindo, is an oxazolidinone presented as an injectable solution for intravenous use. It treats complicated skin and soft‑tissue infections, community‑acquired bacterial pneumonia, nosocomial pneumonia, and infections caused by methicillin‑resistant Staphylococcus aureus (MRSA) or vancomycin‑resistant Enterococcus (VRE) in hospitalized patients.

GNH USA supplies Linezolida Aurobindo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Linezolid is an oxazolidinone antibacterial indicated for several serious bacterial infections.

Complicated skin and soft tissue infections: effective against Gram‑positive pathogens, including MRSA, reducing infection severity. Community‑acquired bacterial pneumonia: eradicates susceptible Streptococcus pneumoniae and other typical organisms. Nosocomial pneumonia: provides coverage for hospital‑acquired Gram‑positive infections. Infections caused by MRSA: active against methicillin‑resistant Staphylococcus aureus strains. Infections caused by VRE: treats vancomycin‑resistant Enterococcus infections where alternatives are limited.

Linezolid may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea - Diarrhea - Headache - Vomiting - Metallic taste - Rash

Serious or Rare Side Effects: - Thrombocytopenia or other blood dyscrasias - Peripheral or optic neuropathy - Serotonin syndrome when combined with serotonergic agents - Lactic acidosis - Hepatic enzyme elevation - Severe hypersensitivity reactions

When using Linezolida Aurobindo, several safety considerations should be observed.

Renal impairment: monitor renal function and adjust therapy as needed. Hepatic impairment: assess liver enzymes regularly during treatment. Concomitant serotonergic drugs: avoid due to risk of serotonin syndrome. Prolonged therapy (>14 days): perform periodic complete blood counts. Pregnancy: safety category unknown; weigh potential benefits against risks. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Linezolid can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Selective serotonin reuptake inhibitors (SSRIs): risk of serotonin syndrome. - Monoamine oxidase inhibitors (MAOIs): may precipitate hypertensive crisis or serotonin syndrome. - Tyramine‑rich foods: potential for hypertensive reactions.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may increase bleeding risk. - Warfarin: linezolid can enhance anticoagulant effect, requiring INR monitoring. - Rifampin: may reduce linezolid plasma concentrations, decreasing efficacy.